Carlsmed, Inc. (CARL)
Official siteHEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ
Market Cap: $469.16M
Last updated: Nov 17, 2026 at 11:03 AM ET
Carlsmed, Inc. (CARL) Stock Forecast
Analysts expect Carlsmed (CARL) to earn -$1.51 per share in the fiscal year ending Dec 31, 2026, on revenue of $79.33M. Of 5 analysts, 5 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 5 ratings average 1.60, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 40.0% |
| Buy | 3 | 60.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 5
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates rise 41.0%.
- Fiscal year ending Dec 31, 2026
- -$1.51
- EPS consensus, revenue $79.33M
- Fiscal year ending Dec 31, 2027
- -$1.56
- EPS consensus, revenue $111.85M
- Next report
- Feb 24, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.51 | -$1.51 to -$1.51 | 1 | $79.33M | $79.04M to $79.90M | 5 |
| Dec 31, 2027 | -$1.56 | -$1.56 to -$1.56 | 1 | $111.85M | $107.22M to $118.50M | 5 |
Quarterly Estimates
The EPS consensus rises from -$0.39 for the quarter ending Dec 31, 2026 to -$0.35 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.39 | -$0.40 to -$0.35 | 7 | $23.22M | $21.98M to $24.46M | 7 |
| Mar 31, 2027 | -$0.35 | -$0.35 to -$0.35 | 1 | $24.56M | $24.21M to $24.80M | 3 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 3 upward and 3 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 1 |
| Fiscal year ending Dec 31, 2027 | 1 | 1 |
| Quarter ending Mar 31, 2027 | 1 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$1.41.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$1.51 | -$1.41 | -$1.41 | -$1.41 | -$1.41 | N/A |
| Fiscal year ending Dec 31, 2027 | -$1.56 | -$1.38 | -$1.38 | -$1.38 | -$1.38 | N/A |
| Quarter ending Mar 31, 2027 | -$0.35 | -$0.31 | -$0.31 | -$0.31 | -$0.31 | N/A |
Frequently Asked Questions About CARL
What is the CARL stock forecast?
Consensus analyst estimates put Carlsmed's EPS at -$1.51 for the fiscal year ending Dec 31, 2026, on revenue of $79.33M. The consensus rating from 5 analysts is Buy.
How do analysts rate CARL stock?
Of 5 analysts covering Carlsmed, 2 rate it Strong Buy, 3 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from CARL next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.51, with estimates from -$1.51 to -$1.51 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.56, with estimates from -$1.56 to -$1.56 from 1 analyst.
What revenue do analysts expect from Carlsmed next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $79.33M, with estimates from $79.04M to $79.90M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $111.85M, with estimates from $107.22M to $118.50M.
How many analysts cover CARL?
5 analysts rate Carlsmed stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.
CARL pages: Overview, Forecast, Competitors